Nevada senators recently held a hearing on a psilocybin legalization bill, discussing a proposed amendment to Nevada psilocybin laws that will remove provisions for therapeutic use, taking extensive testimony from advocates and industry experts– including a personal account from an Assembly lawmaker who shared his own experience after successful ketamine treatment.
The Senate Health and Human Services Committee took up the legislation from Sen. Rochelle Nguyen, which as per the amendment, will seek to remove criminal penalties for possession of up to six ounces for adults 21 and up.
According to Nguyen, undertaking this legislation will reduce the prosecution of people who “wish to heal themselves,” arguing that Nevada residents, law enforcement, and veterans should have the right to explore their treatment options.
What This Entails For Research and Possession
Measures to destigmatize and decriminalize psychedelic use for the systematic treatment of a variety of behavioral conditions continue to gain traction.
This is much to the delight of swathes who struggle to find amicable treatment solutions for their conditions. Moreover, the bill represents positive traction in a discourse loaded with misconceptions.
The measure will streamline the process of research in psilocybin and MDMA and will provide protections for scientists and adults who partake in these studies. The proposed amendment, however, would eliminate this provision.
The revision would instead have less prescriptive language, stating simply that the state Department of Health and Human Services (DHHS) would need to establish a Psychedelic Medicines Working Group to “study psychedelic medicines and make recommendations to the legislature.”
Under the amendment, the possession limit was also increased from four to six ounces.
Nevada Psilocybin Bill In the Long Term
In the Nevada psilocybin bill, the working group will oversee the review of the therapeutic potential of psychedelics, including psilocybin for certain mental health conditions, together with existing laws and regulations governing entheogenic substances at the local, state, and federal levels.
Furthermore, members would need to further develop a strategic and measurable plan to enable access to entheogens and compounds, including but not limited to psilocybin and psilocin products that are affordable, accessible, and safe for consumption.
Consequently, a report with recommendations and findings is due to the legislature by December 31, 2024. So realistically, while the bill won’t get off the ground shortly,
Shedding Light on Psilocybin Therapy
Assemblymember Max Carter (D) testified at the hearing and discussed his personal experience using ketamine therapy to address his chronic depression, highlighting that while effective, it remains short-term.
He also went on to emphasize the vast amount of public servants who could benefit from psilocybin therapy as a result of the nature of their work, such as first responders or veterans.
Further admission was made about the overall stifling nature of legislation when it came to letting researchers do their jobs to understand what the process could entail for sittings to where legislators could be better educated on psychedelics to make more informed decisions about public consumption.
The bill mentions that Nevada “has a high prevalence of adults with behavioral health conditions,” with studies showing psilocybin to have increased efficacy and safety in treating a myriad of these conditions.
With numerous state and local lawmakers throughout the US already enacting legislation, the discourse has been blown wide open–enabling people to develop comprehensive treatment plans for their conditions. Importantly, without the stigma attached.
Enjoyed that first hit? Come chill with us every week at the Friday Sesh for a freshly packed bowl of the week’s best cannabis news!